0.75Open0.97Pre Close1.00K Volume638 Open Interest13.00Strike Price70.44KTurnover94.77%IV6.33%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.60Extrinsic Value100Contract SizeAmericanOptions Type0.4786Delta0.2388Gamma22.24Leverage Ratio-0.0505Theta0.0011Rho10.65Eff Leverage0.0070Vega
uniQure NV Stock Discussion
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Benzinga· 23 mins ago
Revolutionary Hemophilia B Treatment Eliminates Need for Regular Therapy in 94% of Patients
share your thoughts & ideas explain why 2025 will be amazing several break free and run
apextradez Wins so can you
No comment yet